Skip to main content
 

X

 
News

BeiGene News

See all News

  • June 30, 2022
    BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma

  • June 21, 2022
    BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

    BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

  • June 13, 2022
    BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL

    BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL

  • June 13, 2022
    BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

    BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

  • June 10, 2022
    China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

    China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

  • June 10, 2022
    BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress

    BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress

  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160
    Listings
  • 8Internally Developed
    Clinical Candidates
  • 8Marketed
    Products
    in China
  • 1Approved
    Product
    in the U.S.
  • 8,000+Global Team

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksLeapSeagen_LogoAmbrx LogoMirati LogoMEIAmgen logoEUSA LogoAssembly Bio LogohutchmedBio-Thera LogoSinglomics LogostandtxBITT LogoNovartisShoreline

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers